Daraxonrasib Boosts Survival in Metastatic Pancreatic Cancer

Revolution Medicines reported that its oral RAS(ON) inhibitor daraxonrasib significantly extended survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma. In the interim analysis of the global Phase 3 RASolute 302 trial, median overall survival was 13.2 months for daraxonrasib‑treated patients versus 6.7 months for those receiving standard chemotherapy, a 60% reduction in the risk of death (hazard ratio 0.40, p < 0.0001). The trial also met its primary and key secondary endpoints for progression‑free survival and showed a manageable safety profile.

Daraxonrasib targets multiple mutant and wild‑type RAS proteins, addressing the RAS‑driven biology of over 90% of pancreatic cancers. The drug already holds FDA Breakthrough Therapy and Orphan Drug designations, and Revolution Medicines plans to file a New Drug Application in the United States and seek approval abroad. Earlier Phase 1/2 data demonstrated safety and early signs of efficacy in a first‑in‑human study led at Dana‑Farber Cancer Institute.